Verismo Therapeutics, a University of Pennsylvania immunotherapy spinout,

 

Verismo Therapeutics, a University of Pennsylvania immunotherapy spinout, announced a $17M round led by South Korean biotech DongKoo and VC firm HLB.  The startup plans to use the funds to produce therapies against blood, ovarian, and bile duct cancers. Verismo's CEO and Penn professors Michael C. Milone and Donal L. Siegel created the KIR-CAR (killer immunoglobulin-like receptors) platform that targets solid tumors.  Verismo last raised $7M in February in a pre-Series A round led by BRV Capital Management and Ignite Innovation.  The new round brings the startup's total raised to $50M since its inception in 2020.